knowledge -WSS

knowledge

author：comprehensive 2025-09-28 13:23:50 - browse：43136

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

focus

explore

WSS

Do masks work? RCTs can't tell us

Why drug prescriptions should include diagnoses

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

3 hurdles to bringing medical devices to the U.S. market

The story of mRNA: From a loose idea to a tool that may help curb Covid

Paxlovid study fails to answer questions over benefit for broader groups

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Supreme Court strikes down use of affirmative action

Cloning humans is technically possible. It's curious no one has tried

23andMe had bad news about my health. I wish a person had delivered it

Paxlovid study fails to answer questions over benefit for broader groups

Hollywood unions extend contract negotiations for actors

STAT's guide to the next generation of CAR

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why we need to separate burnout from moral injury in health care

Hollywood unions extend contract negotiations for actors

WATCH: Why do fingernails fall off when they're damaged?

explore

STAT's guide to the next generation of CAR

Ask STAT: What do you want to know about ChatGPT in medicine?

Ask STAT: What do you want to know about ChatGPT in medicine?

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Why we need to separate burnout from moral injury in health care

With FDA staff opposed to Sarepta therapy, top official intervened

Wikipedia

focus

explore

entertainment